SOM Biotech Concludes 2020 with Advanced and Robust Pipeline
SOM Biotech, a biopharmaceutical company specialising in the repositioning of existing drugs for the treatment...
SOM0044 is a small molecule for the treatment of Parkinson’s disease.
Parkinson’s disease is a slowly progressive neurodegenerative disorder characterised by bradykinesia, rigidity, tremor at rest, shuffling gait and postural instability. The disease is caused by ageing, genetic and environmental factors. Symptoms usually appear around 60 years of age. Affects an estimated 10 million people worldwide. Available treatments are symptomatic, mainly involving dopaminergic agents for the control of motor function.
SOM Biotech, a biopharmaceutical company specialising in the repositioning of existing drugs for the treatment...
The current Covid-19 pandemic situation has shown that repurposing drugs can be crucial for delivering...
SOM Biotech, a biopharmaceutical company specialising in the repositioning of existing drugs for the treatment...
SOM Biotech, a clinical-stage drug discovery and development company, announces the in vitro validation of...